Myovant Sciences and Pfizer Announce FDA Acceptance of Supplemental New Drug Application for MYFEMBREE®
June 02, 2022 06:50 ET
|
Myovant Sciences, Inc.
BASEL, Switzerland and NEW YORK, June 02, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV) and Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) accepted...
Myovant Sciences Announces Corporate Updates and Financial Results for Fourth Fiscal Quarter and Fiscal Year Ended March 31, 2022
May 10, 2022 06:55 ET
|
Myovant Sciences, Inc.
Fiscal year 2021 total revenue of $231.0 million, including net product revenues of $94.3 million; fourth fiscal quarter 2021 total revenues of $57.6 million, including net product revenue of $32.4...
Myovant Sciences and Accord Healthcare, Ltd. Enter into Exclusive License Agreement to Commercialize ORGOVYX® for Advanced Hormone-Sensitive Prostate Cancer in Europe
May 09, 2022 06:30 ET
|
Myovant Sciences, Inc.
Myovant to receive an upfront payment of $50 million, is eligible to receive commercial launch, sales-based and other milestones totaling up to $90.5 millionMyovant also eligible to receive...
Myovant Sciences and Pfizer Provide Update on Supplemental New Drug Application (sNDA) for MYFEMBREE® for the Management of Moderate to Severe Pain Associated With Endometriosis
May 06, 2022 06:45 ET
|
Myovant Sciences, Inc.
BASEL, Switzerland, and NEW YORK, May 06, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV) and Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has...
Myovant Sciences Announces European Commission Approval for ORGOVYX® (relugolix) for the Treatment of Advanced Hormone-Sensitive Prostate Cancer
April 29, 2022 19:10 ET
|
Myovant Sciences, Inc.
ORGOVYX® is the first and only oral androgen deprivation therapy for advanced hormone-sensitive prostate cancer in EuropeMyovant expects to secure European commercialization partner ahead of...
Myovant Sciences to Host Fourth Fiscal Quarter and Fiscal Year 2021 Earnings Conference Call at 8:30 a.m. Eastern Time on May 10, 2022
April 26, 2022 08:30 ET
|
Myovant Sciences, Inc.
BASEL, Switzerland, April 26, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV) today announced it will host a webcast and conference call to discuss corporate updates and financial results for...
Myovant Sciences and Pfizer Provide Update on Supplemental New Drug Application for MYFEMBREE® for the Management of Moderate to Severe Pain Associated with Endometriosis
April 12, 2022 00:00 ET
|
Myovant Sciences, Inc.
BASEL, Switzerland and NEW YORK, April 12, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV) and Pfizer (NYSE: PFE) announced today an update on the Supplemental New Drug Application (sNDA) for...
Myovant Sciences Receives Positive CHMP Opinion for ORGOVYX® (relugolix) for the Treatment of Advanced Prostate Cancer
February 25, 2022 09:00 ET
|
Myovant Sciences, Inc.
CHMP opinion recommending approval based on data from the global Phase 3 HERO study If approved, ORGOVYX® would be the first and only oral androgen deprivation therapy for advanced hormone-sensitive...
Myovant Sciences to Present at Upcoming Investor Conferences
February 07, 2022 08:30 ET
|
Myovant Sciences, Inc.
BASEL, Switzerland, Feb. 07, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced that David Marek, Chief...
Myovant Sciences Announces Financial Results for Third Quarter of Fiscal Year 2021 and Corporate Updates
January 26, 2022 06:55 ET
|
Myovant Sciences, Inc.
Third fiscal quarter 2021 total revenues of $54.4 million, including net product revenue of $29.3 millionNet product revenue from U.S. sales of ORGOVYX® of $24.4 million, reflecting 40% sequential...